A Comparison of Lepirudin and Argatroban Outcomes
Although both argatroban and lepirudin are used for the management of heparin-induced thrombocytopenia (HIT), data comparing these agents are lacking. The objective of this project was to compare the clinical outcomes of lepirudin vs argatroban therapy. Patients who received a direct thrombin inhibi...
Gespeichert in:
| Veröffentlicht in: | Clinical and applied thrombosis/hemostasis 2005-10, Vol.11 (4), p.371-374 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 374 |
|---|---|
| container_issue | 4 |
| container_start_page | 371 |
| container_title | Clinical and applied thrombosis/hemostasis |
| container_volume | 11 |
| creator | Smythe, Maureen A. Stephens, Jennifer L. Koerber, John M. Mattson, Joan C. |
| description | Although both argatroban and lepirudin are used for the management of heparin-induced thrombocytopenia (HIT), data comparing these agents are lacking. The objective of this project was to compare the clinical outcomes of lepirudin vs argatroban therapy. Patients who received a direct thrombin inhibitor (DTI) from January 2000 to December 2001 were identified. Medical charts were retrospectively reviewed and relevant data extracted. The primary efficacy outcome was effective anticoagulation and the primary safety outcome was major bleeding. Data were analyzed using the t test and Fisher’s exact test. Sixty-one lepirudin patients and 29 argatroban patients received a DTI during the study period. A new diagnosis of HIT was the indication for DTI therapy in 44.8% of argatroban patients and 57.4% of lepirudin patients. Effective anticoagulation was achieved in 77.8% of argatroban patients and 69.5% of lepirudin patients (p = .61). Major bleeding occurred in 10.3% and 11.5% of argatroban and lepirudin patients, respectively (p = 1.0). Argatroban and lepirudin demonstrated comparable safety and efficacy outcomes. |
| doi_str_mv | 10.1177/107602960501100403 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_68710046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_107602960501100403</sage_id><sourcerecordid>2344192095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-8b2dd358cf721f025831e13c2116f91f4c312768d37ba9f2475f0a7a5d7445c73</originalsourceid><addsrcrecordid>eNp90E1LwzAYB_AgipvTL-BBCoK3ujxJmjTHMeYLDHbRc0jzMjrWpibtwW9vxwYDBU_J4ff8k-eP0D3gZwAh5oAFx0RyXGAAjBmmF2gKkpY5EYRejvcR5AcxQTcp7TAGySW_RhPghDHByRTBIluGptOxTqHNgs_WrqvjYOs2063NFnGr-xgq3WaboTehcekWXXm9T-7udM7Q58vqY_mWrzev78vFOjcMaJ-XFbGWFqXxgoDHpCgpOKCGAHAvwTNDgQheWioqLT1hovBYC11YwVhhBJ2hp2NuF8PX4FKvmjoZt9_r1oUhKV6Kw9J8hI-_4C4MsR3_pghlDCTBshgVOSoTQ0rRedXFutHxWwFWhzrV3zrHoYdT9FA1zp5HTv2NYH4ESW_d-d1_In8A1P55eQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2344192095</pqid></control><display><type>article</type><title>A Comparison of Lepirudin and Argatroban Outcomes</title><source>Sage Journals GOLD Open Access 2024</source><creator>Smythe, Maureen A. ; Stephens, Jennifer L. ; Koerber, John M. ; Mattson, Joan C.</creator><creatorcontrib>Smythe, Maureen A. ; Stephens, Jennifer L. ; Koerber, John M. ; Mattson, Joan C.</creatorcontrib><description>Although both argatroban and lepirudin are used for the management of heparin-induced thrombocytopenia (HIT), data comparing these agents are lacking. The objective of this project was to compare the clinical outcomes of lepirudin vs argatroban therapy. Patients who received a direct thrombin inhibitor (DTI) from January 2000 to December 2001 were identified. Medical charts were retrospectively reviewed and relevant data extracted. The primary efficacy outcome was effective anticoagulation and the primary safety outcome was major bleeding. Data were analyzed using the t test and Fisher’s exact test. Sixty-one lepirudin patients and 29 argatroban patients received a DTI during the study period. A new diagnosis of HIT was the indication for DTI therapy in 44.8% of argatroban patients and 57.4% of lepirudin patients. Effective anticoagulation was achieved in 77.8% of argatroban patients and 69.5% of lepirudin patients (p = .61). Major bleeding occurred in 10.3% and 11.5% of argatroban and lepirudin patients, respectively (p = 1.0). Argatroban and lepirudin demonstrated comparable safety and efficacy outcomes.</description><identifier>ISSN: 1076-0296</identifier><identifier>EISSN: 1938-2723</identifier><identifier>DOI: 10.1177/107602960501100403</identifier><identifier>PMID: 16244762</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Aged ; Anticoagulants ; Anticoagulants - therapeutic use ; Female ; Hemorrhage - drug therapy ; Hirudins ; Humans ; Male ; Pipecolic Acids - therapeutic use ; Recombinant Proteins - therapeutic use ; Thrombin - antagonists & inhibitors ; Thrombin - metabolism ; Treatment Outcome</subject><ispartof>Clinical and applied thrombosis/hemostasis, 2005-10, Vol.11 (4), p.371-374</ispartof><rights>Copyright SAGE PUBLICATIONS, INC. Oct 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-8b2dd358cf721f025831e13c2116f91f4c312768d37ba9f2475f0a7a5d7445c73</citedby><cites>FETCH-LOGICAL-c413t-8b2dd358cf721f025831e13c2116f91f4c312768d37ba9f2475f0a7a5d7445c73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/107602960501100403$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/107602960501100403$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21945,27830,27901,27902,44921,45309</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/107602960501100403?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16244762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smythe, Maureen A.</creatorcontrib><creatorcontrib>Stephens, Jennifer L.</creatorcontrib><creatorcontrib>Koerber, John M.</creatorcontrib><creatorcontrib>Mattson, Joan C.</creatorcontrib><title>A Comparison of Lepirudin and Argatroban Outcomes</title><title>Clinical and applied thrombosis/hemostasis</title><addtitle>Clin Appl Thromb Hemost</addtitle><description>Although both argatroban and lepirudin are used for the management of heparin-induced thrombocytopenia (HIT), data comparing these agents are lacking. The objective of this project was to compare the clinical outcomes of lepirudin vs argatroban therapy. Patients who received a direct thrombin inhibitor (DTI) from January 2000 to December 2001 were identified. Medical charts were retrospectively reviewed and relevant data extracted. The primary efficacy outcome was effective anticoagulation and the primary safety outcome was major bleeding. Data were analyzed using the t test and Fisher’s exact test. Sixty-one lepirudin patients and 29 argatroban patients received a DTI during the study period. A new diagnosis of HIT was the indication for DTI therapy in 44.8% of argatroban patients and 57.4% of lepirudin patients. Effective anticoagulation was achieved in 77.8% of argatroban patients and 69.5% of lepirudin patients (p = .61). Major bleeding occurred in 10.3% and 11.5% of argatroban and lepirudin patients, respectively (p = 1.0). Argatroban and lepirudin demonstrated comparable safety and efficacy outcomes.</description><subject>Aged</subject><subject>Anticoagulants</subject><subject>Anticoagulants - therapeutic use</subject><subject>Female</subject><subject>Hemorrhage - drug therapy</subject><subject>Hirudins</subject><subject>Humans</subject><subject>Male</subject><subject>Pipecolic Acids - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Thrombin - antagonists & inhibitors</subject><subject>Thrombin - metabolism</subject><subject>Treatment Outcome</subject><issn>1076-0296</issn><issn>1938-2723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90E1LwzAYB_AgipvTL-BBCoK3ujxJmjTHMeYLDHbRc0jzMjrWpibtwW9vxwYDBU_J4ff8k-eP0D3gZwAh5oAFx0RyXGAAjBmmF2gKkpY5EYRejvcR5AcxQTcp7TAGySW_RhPghDHByRTBIluGptOxTqHNgs_WrqvjYOs2063NFnGr-xgq3WaboTehcekWXXm9T-7udM7Q58vqY_mWrzev78vFOjcMaJ-XFbGWFqXxgoDHpCgpOKCGAHAvwTNDgQheWioqLT1hovBYC11YwVhhBJ2hp2NuF8PX4FKvmjoZt9_r1oUhKV6Kw9J8hI-_4C4MsR3_pghlDCTBshgVOSoTQ0rRedXFutHxWwFWhzrV3zrHoYdT9FA1zp5HTv2NYH4ESW_d-d1_In8A1P55eQ</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Smythe, Maureen A.</creator><creator>Stephens, Jennifer L.</creator><creator>Koerber, John M.</creator><creator>Mattson, Joan C.</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200510</creationdate><title>A Comparison of Lepirudin and Argatroban Outcomes</title><author>Smythe, Maureen A. ; Stephens, Jennifer L. ; Koerber, John M. ; Mattson, Joan C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-8b2dd358cf721f025831e13c2116f91f4c312768d37ba9f2475f0a7a5d7445c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Anticoagulants</topic><topic>Anticoagulants - therapeutic use</topic><topic>Female</topic><topic>Hemorrhage - drug therapy</topic><topic>Hirudins</topic><topic>Humans</topic><topic>Male</topic><topic>Pipecolic Acids - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Thrombin - antagonists & inhibitors</topic><topic>Thrombin - metabolism</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smythe, Maureen A.</creatorcontrib><creatorcontrib>Stephens, Jennifer L.</creatorcontrib><creatorcontrib>Koerber, John M.</creatorcontrib><creatorcontrib>Mattson, Joan C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and applied thrombosis/hemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Smythe, Maureen A.</au><au>Stephens, Jennifer L.</au><au>Koerber, John M.</au><au>Mattson, Joan C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comparison of Lepirudin and Argatroban Outcomes</atitle><jtitle>Clinical and applied thrombosis/hemostasis</jtitle><addtitle>Clin Appl Thromb Hemost</addtitle><date>2005-10</date><risdate>2005</risdate><volume>11</volume><issue>4</issue><spage>371</spage><epage>374</epage><pages>371-374</pages><issn>1076-0296</issn><eissn>1938-2723</eissn><abstract>Although both argatroban and lepirudin are used for the management of heparin-induced thrombocytopenia (HIT), data comparing these agents are lacking. The objective of this project was to compare the clinical outcomes of lepirudin vs argatroban therapy. Patients who received a direct thrombin inhibitor (DTI) from January 2000 to December 2001 were identified. Medical charts were retrospectively reviewed and relevant data extracted. The primary efficacy outcome was effective anticoagulation and the primary safety outcome was major bleeding. Data were analyzed using the t test and Fisher’s exact test. Sixty-one lepirudin patients and 29 argatroban patients received a DTI during the study period. A new diagnosis of HIT was the indication for DTI therapy in 44.8% of argatroban patients and 57.4% of lepirudin patients. Effective anticoagulation was achieved in 77.8% of argatroban patients and 69.5% of lepirudin patients (p = .61). Major bleeding occurred in 10.3% and 11.5% of argatroban and lepirudin patients, respectively (p = 1.0). Argatroban and lepirudin demonstrated comparable safety and efficacy outcomes.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>16244762</pmid><doi>10.1177/107602960501100403</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1076-0296 |
| ispartof | Clinical and applied thrombosis/hemostasis, 2005-10, Vol.11 (4), p.371-374 |
| issn | 1076-0296 1938-2723 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68710046 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Aged Anticoagulants Anticoagulants - therapeutic use Female Hemorrhage - drug therapy Hirudins Humans Male Pipecolic Acids - therapeutic use Recombinant Proteins - therapeutic use Thrombin - antagonists & inhibitors Thrombin - metabolism Treatment Outcome |
| title | A Comparison of Lepirudin and Argatroban Outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A39%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comparison%20of%20Lepirudin%20and%20Argatroban%20Outcomes&rft.jtitle=Clinical%20and%20applied%20thrombosis/hemostasis&rft.au=Smythe,%20Maureen%20A.&rft.date=2005-10&rft.volume=11&rft.issue=4&rft.spage=371&rft.epage=374&rft.pages=371-374&rft.issn=1076-0296&rft.eissn=1938-2723&rft_id=info:doi/10.1177/107602960501100403&rft_dat=%3Cproquest_AFRWT%3E2344192095%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2344192095&rft_id=info:pmid/16244762&rft_sage_id=10.1177_107602960501100403&rfr_iscdi=true |